IL6 and prostate cancer: Based on the present results, we have updated our previously-reported melatonin MT1 receptor antiproliferative pathway in prostate cancer [23] with bi-directional positive interactions between AR-V7 and NF-κB/IL-6 signaling (Figure 8).